AliveCor’s SEARCH-AF trial results: atrial fibrillation was identified in 1.5% of 1,000 customers

AliveCor unveiled study results of the SEARCH-AF study, screened 1,000 customers over 65 years old for an abnormal heart rhythm, atrial fibrillation (AF), in 10 community pharmacies in suburban Sydney, Australia. The AliveCor Heart Monitor was used to capture 30-60 second ECG recordings and wirelessly transmit the recordings to study cardiologists. This simple method enabled study cardiologists to identify patients at risk of stroke because of unknown AF, and flag them for additional evaluation.

New AF was identified in 1.5% of the people screened, all at high risk of stroke. Most of the people with newly discovered AF had no symptoms, and may never have sought medical advice.

This study highlights one application of mobile ECG technology that can help facilitate cost-effective preventative medical care. Additionally, the study found the incremental cost-effectiveness ratio was just over $4,000 for an increase of one Quality Adjusted Life Year and just over $20,000 for preventing one stroke. If asymptomatic people with AF are detected in this way and given warfarin or other newer powerful blood thinners, the risk of stroke can potentially be reduced by two thirds.

“We believe these findings have great significance for health providers and should become part of routine practice as this type of screening program is a cost effective way to identify patients with asymptomatic atrial fibrillation; a condition that can lead to potentially life threatening complications,” said Euan Thomson, president and chief executive officer of AliveCor.

The AliveCor Heart Monitor is the only FDA cleared mobile ECG recorder that supports both iPhone and Android smartphones.